259 related articles for article (PubMed ID: 11950383)
1. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.
Wahlqvist P; Junghard O; Higgins A; Green J
Pharmacoeconomics; 2002; 20(4):267-77. PubMed ID: 11950383
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK.
Wahlqvist P; Junghard O; Higgins A; Green J
Pharmacoeconomics; 2002; 20(4):279-87. PubMed ID: 11950384
[TBL] [Abstract][Full Text] [Related]
3. Esomeprazole: a review of its use in the management of acid-related disorders.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Remák E; Brown RE; Yuen C; Robinson A
Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
[TBL] [Abstract][Full Text] [Related]
6. [Pharma clinics medication of the month. Esomeprazole].
Louis E
Rev Med Liege; 2002 Sep; 57(9):610-2. PubMed ID: 12440351
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Kivioja A; Linnosmaa I; Vehviläinen A; Vohlonen I
Eur J Pharm Sci; 2004 Feb; 21(2-3):171-8. PubMed ID: 14757488
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months.
Talley NJ; Venables TL; Green JR; Armstrong D; O'Kane KP; Giaffer M; Bardhan KD; Carlsson RG; Chen S; Hasselgren GS
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):857-63. PubMed ID: 12172406
[TBL] [Abstract][Full Text] [Related]
9. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.
Scholten T; Teutsch I; Bohuschke M; Gatz G
Clin Drug Investig; 2007; 27(4):287-96. PubMed ID: 17358101
[TBL] [Abstract][Full Text] [Related]
10. On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations.
Inadomi JM
Pharmacoeconomics; 2002; 20(9):565-76. PubMed ID: 12141885
[TBL] [Abstract][Full Text] [Related]
11. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
Orr WC
Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):113-20. PubMed ID: 15647651
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.
Hughes DA; Bodger K; Bytzer P; de Herdt D; Dubois D
Pharmacoeconomics; 2005; 23(10):1031-41. PubMed ID: 16235976
[TBL] [Abstract][Full Text] [Related]
13. Review of esomeprazole in the treatment of acid disorders.
Johnson DA
Expert Opin Pharmacother; 2003 Feb; 4(2):253-64. PubMed ID: 12562316
[TBL] [Abstract][Full Text] [Related]
14. Esomeprazole.
Spencer CM; Faulds D
Drugs; 2000 Aug; 60(2):321-9; discussion 330-1. PubMed ID: 10983736
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.
Stålhammar NO; Carlsson J; Peacock R; Müller-Lissner S; Bigard MA; Porro GB; Ponce J; Hosie J; Scott M; Weir DG; Fulton C; Gillon K; Bardhan KD
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):483-97. PubMed ID: 10662395
[TBL] [Abstract][Full Text] [Related]
17. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
18. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery.
Myrvold HE; Lundell L; Miettinen P; Pedersen SA; Liedman B; Hatlebakk J; Julkunen R; Levander K; Lamm M; Mattson C; Carlsson J; Ståhlhammar NO;
Gut; 2001 Oct; 49(4):488-94. PubMed ID: 11559644
[TBL] [Abstract][Full Text] [Related]
19. On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease.
Pace F; Pallotta S; Bianchi Porro G
Dig Liver Dis; 2002 Dec; 34(12):870-7. PubMed ID: 12643297
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD.
Bojke L; Hornby E; Sculpher M;
Pharmacoeconomics; 2007; 25(10):829-41. PubMed ID: 17887805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
